Oslo May 07, 2021 - Observe Medical ASA (OSE: OBSRV), announces that Nya
Karolinska Sjukhuset, Sweden, prepares new studies to broaden the clinical scope
of use for Sippi® automated, digital urine measurement system, building further
on the results from the recent dissertation by Dr Martin Slettengren.

Following the recent dissertation by Dr. Martin Slettengren, "Evaluation of an
automatic urinometer including use of silicone oil to decrease biofilm formation
due to proteinuria, hemoglobinuria and bacterial growth", the team at thorax
Intensive Care Unit at Nya Karolinska Sjukhuset, led by Professor Jan van der
Linden, has submitted applications for ethical approval for new studies, with
the aim of broadening the clinical scope of use for Sippi®. Such studies will
support  and strengthen the Sippi® commercial opportunity.

"During the COVID-19 pandemics, many patients suffer from acute kidney injury
(AKI). AKI is a major clinical challenge in hospitals, often discovered too
late, causing severe clinical complications, patient suffering, and costs for
the healthcare system. Due to the high data collection frequency supported by
proprietary, patented technology, Sippi® is uniquely positioned to identify new
diagnostics predictors of AKI," says Björn Larsson, CEO of Observe Medical.

"The unique technology of the Sippi capacitance based digital urine volume
measurement system, allows for identifying new clinical diagnostic parameters,
for example for acute kidney injury, based on more detailed urine flow
measurements," comments Professor Jan van der Linden at Nya Karolinska
Sjukhuset.

Observe Medical's product Sippi® is the only automated digital urine meter with
possibility for wireless data transfer (SippLinkT) to the hospital patient data
management systems and detects (SippSense®) and hinders (Sippcoat®) biofilm
formation, that can lead to urinary infections.

Observe Medical current focus is the clinical rollout of Sippi® in the Nordic
region and selected countries in rest of Europe to get systems in clinical use,
and to receive customer feedback.

"We are excited about the scientific collaboration with Nya Karolinska
Sjukhuset, further strengthening the clinical evidence, value proposition and
thus the commercial opportunity for Sippi®," states Björn Larsson, CEO of
Observe Medical ASA.



For further information, please contact:

Observe Medical: Björn Larsson, CEO, +46 76 620 17 25,
bjorn.larsson@observemedical.com



About Observe Medical https://observemedical.com/

Observe Medical develops and markets and sells innovative hospital products that
contribute to increased patient safety and a more efficient care system. The
company's ambition is to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in the areas of Urine measurement, Anesthesiology/ICUs and wound care, in
combination with targeted M&A. The company's headquarters is in Oslo, Norway and
its operations is based out of Gothenburg, Sweden. Observe Medical has a direct
sales organization in the Nordics and a distributor network internationally.
Observe Medical's product Sippi® is the only automated digital urine meter with
possibility for wireless data transfer to the hospital patient data management
systems and hinders biofilm formation that can lead to urinary infections
(Sippcoat®). Sippi® is currently being launched with focus on selected markets
and hospitals in Nordics and in Europe.